Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial
Marius Trøseid, José Ramón Arribas, Lambert Assoumou, Aleksander Rygh Holten et autres
BACKGROUND: Baricitinib has shown efficacy in hospitalized patients with COVID-19, but no placebo-controlled trials have focused specifically on severe/critical COVID, including vaccinated participants. METHODS: Bari-SolidAct is a phase-3, multicentre, randomised, double-blind, placebo-controlled trial, enrolling participants from June 3, 2021 to March 7, …
no, es, fr, it, ie, be, at, pt, lu, de, sk, hu, gr, cz, ch, tr (code pays fourni par la source)
48 citations
Critical Care